Zum Hauptinhalt springen

Primer set and method for detecting telomerase activity

Institute of Zoology, Chinese Academy of Sciences
2024
Online Patent

Titel:
Primer set and method for detecting telomerase activity
Autor/in / Beteiligte Person: Institute of Zoology, Chinese Academy of Sciences
Link:
Veröffentlichung: 2024
Medientyp: Patent
Sonstiges:
  • Nachgewiesen in: USPTO Patent Grants
  • Sprachen: English
  • Patent Number: 11859,245
  • Publication Date: January 02, 2024
  • Appl. No: 16/939098
  • Application Filed: July 27, 2020
  • Assignees: INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES (Beijing, CN)
  • Claim: 1. A primer set for detecting telomerase activity, the primer set comprising a first primer set or a second primer set; wherein: the first primer set comprises: an upstream primer having a sequence of SEQ ID NO: 8; and a downstream primer selected from the group consisting of having a sequence of SEQ ID NO: 4 or SEQ ID NO: 5; the second primer set comprises: an upstream primer having a sequence of SEQ ID NO: 7; and a downstream primer having a sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.
  • Claim: 2. The primer set of claim 1 , wherein a 5′-end of the upstream primer of the first primer set and a 5′-end of the upstream primer of the second primer set are both labeled with a fluorescent reporter group.
  • Claim: 3. The primer set of claim 2 , wherein the fluorescent reporter group is located on an iso-dC nucleotide or a dCTP nucleotide at the 5′-end of the upstream primer.
  • Claim: 4. The primer set of claim 2 , wherein the fluorescent reporter group is selected from the group consisting of fluorescein amidite, boron-dipyrromethene, and tetramethylrhodamine.
  • Claim: 5. The primer set of claim 3 , wherein the fluorescent reporter group is selected from the group consisting of fluorescein amidite, boron-dipyrromethene, and tetramethylrhodamine.
  • Claim: 6. A method for detecting telomerase activity of a biological sample using the primer set of claim 1 , the method comprising: 1) lysing the biological sample with a 3-((3-cholamidopropyl)dimethylammonio)propanesulfonate (CHAPS) lysis buffer to obtain a cell lysate solution; 2) performing a telomerase extension in the cell lysate solution in the presence of the upstream primer of the first primer set or the second primer set of the primer set to obtain a telomerase template; and 3) conducting a qPCR amplification with the telomerase template in the presence of a corresponding downstream primer of the upstream primer of the first primer set or the second primer set used in the telomerase extension in 2).
  • Claim: 7. The method of claim 6 , wherein in 1), obtaining the cell lysate solution comprises: suspending cells of the biological sample in a phosphate buffer saline (PBS) solution, centrifuging the PBS solution comprising the cells at 500×g for 3 min, removing a supernatant of the PBS solution and repeating the centrifuging and removing the supernatant for 3 times; resuspending the cells in an isotonic buffer, dispersing the cells, adding the cells to 2 volumes of CHAPS lysis buffer with respect to a volume of the cells, lysing the cells on an ice for 30 min, centrifuging the cells at 16000×g for 20 min, collecting a supernatant and/or storing the supernatant at −80° C.
  • Claim: 8. The method of claim 6 , wherein in 1), obtaining the cell lysate solution comprises: adding 1-175 μL of the CHAPS lysis buffer to a PCR tube, aspirating single or multiple cells of the biological sample into the PCR tube by a flow cytometer or a glass tube under a microscope, and lysing the cells on an ice for 10-30 min to obtain the cell lysate solution.
  • Claim: 9. The method of claim 6 , wherein the method is implemented in a PCR tube provided with 20-μL of a reaction solution comprising 10 μL of 2×PCR mix, 0.8 μL of the upstream primer, 0.8 μL of the downstream primer, 2 μL of the cell lysate solution, and 6.4 μL of double distilled water; or the method is implemented in a PCR tube provided with 10 μL of a reaction solution comprising 5 μL of 2×PCR mix, 0.4 μL of the upstream primer, 0.4 μL of the downstream primer, 1 μL of the cell lysate solution, 0.15 μL of dimethylsulfoxide (DMSO), 0.15 μL of 10 mg/mL bovine serum albumin (BSA), and 2.9 μL of double distilled water.
  • Claim: 10. The method of claim 9 , wherein the reaction solution is treated under an extension reaction program and a PCR reaction program consecutively; the extension reaction program comprises incubation at 25° C. for 25 min, and denaturation at 94° C. for 2 min; the PCR reaction program comprises: a) denaturation at 94° C. for 30 s; b) annealing at 57-60° C. for 30 s; c) extension at 72° C. for 30 s; d. repeating operations b)-c) 45-50 times; and e) extension at 72° C. for 10 min.
  • Claim: 11. The method of claim 6 , wherein the method is implemented in a PCR tube provided with 10 μL of a first reaction system comprising 5 μL of 2×PCR mix, 0.8 μL of the upstream primer, 2 μL of the cell lysate solution, and 2.2 μL of double distilled water, and 20 μL of a second reaction system comprising 5 μL of 2×PCR mix, 0.8 μL of the downstream primers, 10 μL of telomerase template, and 4.2 μL of double distilled water; and the first reaction system and the second reaction system are added to the PCR tube in two steps.
  • Claim: 12. The method of claim 11 , wherein the PCR tube is treated under an extension reaction program and a PCR reaction program consecutively; the extension reaction program comprises incubation at 25° C. for 10-25 min, and denaturation at 94° C. for 5 min; the PCR reaction program comprises: a) denaturation at 94° C. for 2 min; b) denaturation at 94° C. for 30 s; c) annealing at 57-60° C. for 30 s; d) extension at 72° C. for 30 s; e) repeating operations b)-d) 45-50 times; and f) extension at 72° C. for 10 min.
  • Claim: 13. The method of claim 6 , wherein the CHAPS lysis buffer comprises 15 mM of Tris-HCl (pH 7.5), 2 mM of MgCl 2 , 1.5 mM of ethylene glycol tetraacetic acid (EGTA), 0.75% of CHAPS (m/v), 15% of glycerol (v/v), 7.5 mM of dithiothreitol (DTT), 0.75 mM of a protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF), 1.5 U/μL of a RNase inhibitor, and 0.6 mg/mL of BSA.
  • Patent References Cited: 105648051 June 2016
  • Other References: Szatmari et al., Analytical Biochemistry 282, 80-88, (Year: 2000). cited by examiner
  • Primary Examiner: Wilder, Cynthia B
  • Attorney, Agent or Firm: MATTHIAS SCHOLL P.C. ; Scholl, Matthias

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -